Myasthenia Gravis

Chapter
Part of the Emergency Management in Neurology book series (EMN)

Abstract

Myasthenia gravis (MG) is an acquired autoimmune disease of the neuromuscular junction characterized by fluctuating weakness and exhaustion of the striated skeletal muscle [1, 2].

References

  1. 1.
    Drachman DB (1994) Myasthenia gravis. N Engl J Med 330:1797–1810CrossRefPubMedGoogle Scholar
  2. 2.
    Vincent A (2002) Unraveling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797–804CrossRefPubMedGoogle Scholar
  3. 3.
    Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475–490CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368CrossRefPubMedGoogle Scholar
  5. 5.
    McConville J, Farrugia ME, Beeson D et al (2004) Detection and characterization of musk antibodies in seronegative myasthenia gravis. Ann Neurol 55(4):580–584CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang B, Tzartos JS, Belimezi M et al (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445–451CrossRefPubMedGoogle Scholar
  7. 7.
    Cossins J, Belaya K, Zolowska K et al (2012) The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 1275:123–128CrossRefPubMedGoogle Scholar
  8. 8.
    Carr AS, Cr C, McCarron PO et al (2010) A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 18(10):46CrossRefGoogle Scholar
  9. 9.
    Engel AG (1994) Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong C (eds) Myology. McGraw-Hill, New York, pp 1769–1797Google Scholar
  10. 10.
    Karlin A, Akabas MH (1995) Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15(6):1231CrossRefPubMedGoogle Scholar
  11. 11.
    Drachman DB, Adams RN, Josifek LF, Self SG (1982) Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 307:769CrossRefPubMedGoogle Scholar
  12. 12.
    Hohlfeld R, Wekerle H (2008) Reflections on the “intrathymic pathogenesis” of myasthenia gravis. Neuroimmunology 201–202:21–27CrossRefGoogle Scholar
  13. 13.
    Liyanage Y, Hoch W, Beeson D, Vincent A (2002) The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 25(1):4CrossRefPubMedGoogle Scholar
  14. 14.
    Ohta K, Shigemoto K, Kubo S et al (2004) MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 62:2132CrossRefPubMedGoogle Scholar
  15. 15.
    Ghazanfari N, Fernandez KJ, Murata Y, Morsch M, Ngo ST, Reddel SW, Noakes PG, Phillips WD (2011) Muscle specific kinase: organiser of synaptic membrane domains. Int J Biochem Cell Biol 43(3):295–298CrossRefPubMedGoogle Scholar
  16. 16.
    Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A (2008) IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain 131:1940CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G (2007) Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68(8):609CrossRefPubMedGoogle Scholar
  18. 18.
    Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69(2):418–422CrossRefPubMedGoogle Scholar
  19. 19.
    Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, Melms A, Kröger S (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259(3):427CrossRefPubMedGoogle Scholar
  20. 20.
    Hoosterhuis HJGH (1997) Clinical aspects and epidemiology. In: Myasthenia gravis. Groningen Neurological Press, Groningen, pp 17–48Google Scholar
  21. 21.
    Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141CrossRefPubMedGoogle Scholar
  22. 22.
    Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A et al (1990) A multicenter follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 237:339–344CrossRefPubMedGoogle Scholar
  23. 23.
    Osserman KE, Jenkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38:497–537PubMedGoogle Scholar
  24. 24.
    Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis. Recommendations for clinical research standards. Neurology 55:16–23CrossRefGoogle Scholar
  25. 25.
    Sethi KD, Rivner MH (1987) Swift TR Ice pack test for myasthenia gravis. Neurology 37(8):1383CrossRefPubMedGoogle Scholar
  26. 26.
    Golnik KC, Pena R, Lee AG, Eggenberger ER (1999) An ice test for the diagnosis of myasthenia gravis. Ophthalmology 106(7):1282CrossRefPubMedGoogle Scholar
  27. 27.
    Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48:1246–1252CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Choi Decroos E, Hobson-Webb LD, Juel VC, Massey JM, Sanders DB (2014) Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve 49(1):30–34CrossRefPubMedGoogle Scholar
  29. 29.
    Vincent A, McConville J, Farrugia ME, Newsom-Davis J (2004) Seronegative myasthenia gravis. Semin Neurol 24(1):125CrossRefPubMedGoogle Scholar
  30. 30.
    Caress JB, Hunt CH, Batish SD (2005) Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 62(6):1002CrossRefPubMedGoogle Scholar
  31. 31.
    Baggi F, Andreetta F, Antozzi C, Simoncini O, Confalonieri P, Labeit S, Cornelio F, Mantegazza R (1998) Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma. Ann N Y Acad Sci 841:538–541CrossRefPubMedGoogle Scholar
  32. 32.
    Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez L et al (2001) Anti-Titin antibodies in myasthenia gravis. Right association with thymoma and heterogeneity of nonthymomatous patients. Arch Neurol 58:885–890CrossRefPubMedGoogle Scholar
  33. 33.
    Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D (1992) Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 15(6):720CrossRefPubMedGoogle Scholar
  34. 34.
    AAEM Quality Assurance Committee, American Association of Electrodiagnostic Medicine (2001) Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 24(9):1239CrossRefGoogle Scholar
  35. 35.
    Castleman B (1966) The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad Sci 135(1):496CrossRefPubMedGoogle Scholar
  36. 36.
    Rowland LP (1980) Controversies about the treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry 43:644–659CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15:291–298CrossRefPubMedGoogle Scholar
  38. 38.
    Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F (1984) Myasthenia gravis: prolonged treatment with steroids. Neurology 34:170–174CrossRefPubMedGoogle Scholar
  39. 39.
    Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR (2005) Coticosteroids for myasthenia gravis. Cochrane Database Syst Rev (2):CD002828Google Scholar
  40. 40.
    Palace J, Newsom-Davis J, Lecky B, The Myasthenia Gravis Study Group (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50:1778–1783CrossRefPubMedGoogle Scholar
  41. 41.
    Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ (1984) Azathioprine in the treatment of myasthenia gravis. Ann Neurol 15:602–605CrossRefPubMedGoogle Scholar
  42. 42.
    Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F (1988) Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 235:449–453CrossRefPubMedGoogle Scholar
  43. 43.
    Hohlfeld R, Toyka K, Besinger UA, Gerhold B, Heininger K (1985) Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long term azathioprine. Ann Neurol 17:238–242CrossRefPubMedGoogle Scholar
  44. 44.
    De Feo LG, Schottlender J, Martelli NA, Molfino NA (2002) Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve (1):31–36Google Scholar
  45. 45.
    Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719–724CrossRefPubMedGoogle Scholar
  46. 46.
    Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K (1993) A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 681:539–551CrossRefPubMedGoogle Scholar
  47. 47.
    Ciafaloni E, Nikhar NK, Massey JM, Sanders DB (2000) Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 55:448–450CrossRefPubMedGoogle Scholar
  48. 48.
    Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB (2001) Mycophenale mofetil for myasthenia gravis. Neurology 56:97–99CrossRefPubMedGoogle Scholar
  49. 49.
    Chaudhry V, Cornblath DR, Griffin JW, O’Brien R, Drachman DB (2001) Mycophonelate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56:94–96CrossRefPubMedGoogle Scholar
  50. 50.
    Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB (2003) Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61:1438–1440CrossRefPubMedGoogle Scholar
  51. 51.
    Hehir MK, Burns TM, Alpers J et al (2010) Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 41:593CrossRefPubMedGoogle Scholar
  52. 52.
    Sanders DB, Hart IK, Mantegazza R et al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400CrossRefPubMedGoogle Scholar
  53. 53.
    Muscle Study Group (2008) A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71:394CrossRefGoogle Scholar
  54. 54.
    Meriggioli MN, Rowin J, Richman JG, Leurgans S (2003) Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 998:494CrossRefPubMedGoogle Scholar
  55. 55.
    Heckmann JM, Rawoot A, Bateman K et al (2011) A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 11:97CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T, Japanese FK506 MG Study Group (2003) Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 28:570–574CrossRefPubMedGoogle Scholar
  57. 57.
    Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M (2002) Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 9(6):627–628CrossRefPubMedGoogle Scholar
  58. 58.
    Lebrun C, Bourg V, Tieulie N, Thomas P (2009) Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 16:246CrossRefPubMedGoogle Scholar
  59. 59.
    Zebardast N, Patwa HS, Novella SP, Goldstein JM (2010) Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 41:375CrossRefPubMedGoogle Scholar
  60. 60.
    Stein B, Bird SJ (2011) Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. J Clin Neuromuscul Dis 12:163CrossRefPubMedGoogle Scholar
  61. 61.
    Díaz-Manera J, Martínez-Hernández E, Querol L et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189CrossRefPubMedGoogle Scholar
  62. 62.
    Rowin J, Meriggioli MN, Tüzün E et al (2004) Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63:2390CrossRefPubMedGoogle Scholar
  63. 63.
    Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C, for the Myasthenia Gravis Clinical Study Group (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41:789–796CrossRefPubMedGoogle Scholar
  64. 64.
    Gajdos P, Chevret S, Toyka K (2002) Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev (4):CD002275Google Scholar
  65. 65.
    Gajdos P, Chevret S, Toyka K (2012) Intravenous immunoglobulins for myasthenia gravis. Cochrane Database Syst Rev (12):CD002277Google Scholar
  66. 66.
    Barth D, Nouri MN, Ng E et al (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017–2023CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Wolfe GI, Kaminski HJ, Jaretzki A et al (1998) Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci 998:473–480CrossRefGoogle Scholar
  68. 68.
    Gronseth GS, Barohn RJ (2000) Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:7–15CrossRefPubMedGoogle Scholar
  69. 69.
    Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 64:536–538CrossRefPubMedGoogle Scholar
  70. 70.
    Mantegazza R, Baggi F, Bernasconi P, Antozzi C, Confalonieri P, Novellino L, Spinelli L, Ferrò MT, Beghi E, Cornelio F (2003) Video-assisted thoracoscopic extended thymectomy and extended transternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci 212:31–36CrossRefPubMedGoogle Scholar
  71. 71.
    Wendell LC, Levine JM (2011) Myasthenic crisis. Neurohospitalist 1(1):16–22CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D (1997) Therapy of myasthenic crisis. Crit Care Med 25(7):1228–1235CrossRefPubMedGoogle Scholar
  73. 73.
    Mier A, Laroche C, Green M (1990) Unsuspected myasthenia gravis presenting as respiratory failure. Thorax 45(5):422CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Juel VC (2004) Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 24(1):75CrossRefPubMedGoogle Scholar
  75. 75.
    Jani-Acsadi A, Lisak RP (2007) Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci 261(1-2):127–133CrossRefPubMedGoogle Scholar
  76. 76.
    Chaudhuri A, Behan PO (2009) Myasthenic crisis. QJM 102(2):97–107CrossRefPubMedGoogle Scholar
  77. 77.
    Bril V, Barnett-Tapia C, Barth D et al (2012) IVIg and PLEX in the treatment of myasthenia gravis. Ann N Y Acad Sci 1275:1–6CrossRefPubMedGoogle Scholar
  78. 78.
    Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72(18):1548CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of NeuroscienceASST LeccoLeccoItaly

Personalised recommendations